Your Best Stock
Stocks Biotechnology VRTX

Vertex Pharmaceuticals VRTX

US equityMarket cap rank #116BiotechnologyGene Editing
$520.94
+$4.60 (+0.89%)
Market open · Sep 24, 1:10 pm ET
After hours $517.00 +0.13%
Open$515.56
Prev close$516.34
Day range$515.30 – $528.89
Volume332.9K
Market cap$132.04B
P/E (TTM)30.3
Dividend yield

Earnings

Average move on report day±4.9%last 15 reports
Closed higher6 of 1540% of the time
Best reaction+9.0%
Worst reaction-20.6%

Stock move on the day after each report

+3.1%2023/Q2-1.9%2023/Q3-3.0%2023/Q4-2.2%2024/Q2+5.7%2024/Q3-3.1%2024/Q4-10.0%2025/Q1-20.6%2025/Q2-1.0%2025/Q3+5.7%2025/Q4-1.3%2026/Q1+1.7%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q32 Nov 2026After Market
2026/Q23 Aug 2026After Market±26.7%+1.70%Within range
2026/Q14 May 2026After Market±25.7%-1.28%Within range
2025/Q412 Feb 2026After Market±37.6%+5.69%Within range
2025/Q33 Nov 2025After Market±29.3%-1.02%Within range
2025/Q24 Aug 2025After Market±31.8%-20.60%Within range
2025/Q15 May 2025After Market±23.1%-10.03%Within range
2024/Q410 Feb 2025After Market±22.6%-3.14%Within range
2024/Q34 Nov 2024After Market±25.0%+5.73%Within range
2024/Q21 Aug 2024After Market±26.0%-2.24%Within range
2023/Q45 Feb 2024After Market±20.0%-2.98%Within range
2023/Q36 Nov 2023After Market±15.3%-1.95%Within range
2023/Q21 Aug 2023After Market±12.6%+3.07%Within range
2023/Q11 May 2023After Market±14.9%+0.30%Within range
2022/Q47 Feb 2023After Market±12.7%-4.93%Within range
2022/Q327 Oct 2022After Market±14.1%+9.03%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q2

By business line

  • TRIKAFTA/KAFTRIO$2.50B 74.9%
  • ALYFTREK$573.60M 17.2%
  • Other cystic fibrosis (CF) products$137.10M 4.1%
  • CASGEVY$76.40M 2.3%
  • JOURNAVX$49.60M 1.5%

Latest reported quarter: Q2, ended Jun 2026

Revenue$3.33B+12.5% YoY
Operating profit$1.27B+9.9% YoY
Net profit$1.10B+6.5% YoY
Diluted EPS$4.31+8.0% YoY
Free cash flow$1.01B+9.3% YoY
Operating cash flow$1.13B

Revenue, last 8 quarters

$2.8BSep '24$2.9BDec '24$2.8BMar '25$3.0BJun '25$3.1BSep '25$3.2BDec '25$3.0BMar '26$3.3BJun '26

Net profit, last 8 quarters

$1.0BSep '24$913.0MDec '24$646.3MMar '25$1.0BJun '25$1.1BSep '25$1.2BDec '25$1.0BMar '26$1.1BJun '26

Profitability & balance sheet

Gross margin86.0%
Operating margin37.9%
Net margin35.0%
Return on equity23.5%
Return on assets17.1%
Return on invested capital19.5%
Current ratio3.19
Liabilities / assets26.2%
Cash & investments$7.85B
Total debt$1.98B
Net cash (debt)$5.87B
Free cash flow / sales30.2%
Scroll to Top